Cemiplimab monotherapy for first-line treatment of advanced non …
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00228-2/fulltext
WEBFeb 13, 2021 · In EMPOWER-Lung 1, cemiplimab was superior to chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50% and without EGFR, ALK, or ROS1 aberrations. Treatment with cemiplimab resulted in significantly longer overall survival and progression-free survival, reducing the risk of …
DA: 34 PA: 39 MOZ Rank: 28